EMBO Mol Med

Ribonucleotide reductase inhibitors suppress SAMHD 1 ara‐ CTP ase activity enhancing cytarabine efficacy

Rudd SG, Tsesmetzis N, Sanjiv K, ..., Helleday T, Herold N

EMBO Mol Med 12 (3) - [2020-03-06; online 2020-01-17]

Chemical Biology Consortium Sweden (CBCS) [Collaborative]

Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma

Mohlin S, Hansson K, Radke K, ..., von Stedingk K, Bexell D

EMBO Mol Med 11 (8) e10058 [2019-08-00; online 2019-07-16]

NGI Uppsala (Uppsala Genome Center) [Service] National Genomics Infrastructure [Service] Targeted and Structural Proteomics [Service]

Anti‐tumor effects of PIM / PI 3K/ mTOR triple kinase inhibitor IBL ‐302 in neuroblastoma

Mohlin S, Hansson K, Radke K, ..., Stedingk K, Bexell D

EMBO Mol Med - (-) - [2019-07-16; online 2019-07-16]

NGI Uppsala (Uppsala Genome Center) [Service] National Genomics Infrastructure [Service]

Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies.

Ayoglu B, Chaouch A, Lochmüller H, ..., Nilsson P, Al-Khalili Szigyarto C

EMBO Mol Med 6 (7) 918-936 [2014-07-00; online 2014-06-13]

Translational Plasma Profiling [Collaborative]

CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer.

Cepeda D, Ng HF, Sharifi HR, ..., Larsson LG, Sangfelt O

EMBO Mol Med 5 (7) 1067-1086 [2013-07-00; online 2013-06-19]

Tissue Profiling